文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

伴环形铁粒幼细胞的难治性贫血(RARS)及伴血小板增多的RARS:2019年诊断、风险分层与管理更新

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
PubMed 文献 · Am J Hematol · 2019-01-24

该综述更新了伴环形铁粒幼细胞(RS)的难治性贫血(RARS)及其伴血小板增多亚型的诊断、风险分层与管理。MDS-RS为低危MDS,诊断需<5%骨髓原始细胞且≥15%骨髓RS(SF3B1突变时≥5%);MDS/MPN-RS-T需血小板≥450×10⁹/L及大而不典型巨核细胞。SF3B1突变见于≥80%的MDS-RS-SLD和MDS/MPN-RS-T。贫血和铁过载治疗类似低危MDS和MPN,luspatercept将大幅提升贫血管理能力;MDS/MPN-RS-T中阿司匹林治疗合理,尤其伴JAK2V617F时,但降血小板药物的价值仍不确定。

要点

  • MDS-RS诊断需骨髓原始细胞<5%且骨髓RS≥15%(SF3B1突变时≥5%)。
  • MDS/MPN-RS-T诊断需血小板≥450×10⁹/L及大而不典型巨核细胞。
  • SF3B1突变见于≥80%的MDS-RS-SLD和MDS/MPN-RS-T,与骨髓RS强相关。

核心结论

  • MDS-RS为低危MDS,MDS/MPN-RS-T预后优于MDS-RS-SLD但劣于ET,两者白血病转化风险均低。
  • 贫血和铁过载治疗类似低危MDS和MPN,luspatercept将大幅提升贫血管理能力。
  • MDS/MPN-RS-T中阿司匹林治疗合理,尤其伴JAK2V617F时,但降血小板药物的价值仍不确定。

研究设计与样本

  • 本文为2019年关于RARS及RARS-T诊断、风险分层与管理的更新综述。

主要发现

  • MDS-RS表现为单系或多系病态造血,骨髓原始细胞<5%,骨髓RS≥15%(SF3B1突变时≥5%)。
  • MDS/MPN-RS-T具有MDS-RS-SLD诊断特征,同时血小板≥450×10⁹/L并见大而不典型巨核细胞。
  • SF3B1突变见于≥80%的MDS-RS-SLD和MDS/MPN-RS-T患者,与骨髓RS强相关;MDS/MPN-RS-T还可见JAK2V617F、ASXL1、DNMT3A、SETBP1和TET2突变。
  • 多数MDS-RS-SLD患者按修订版IPSS归入较低危组;MDS/MPN-RS-T预后优于MDS-RS-SLD但劣于ET,两者白血病转化风险均低。
  • 两种疾病均可出现贫血和铁过载,处理类似低危MDS和MPN;luspatercept作为首创红细胞成熟剂将大幅提升贫血管理能力。

关键数值与推荐

  • MDS-RS诊断标准:骨髓原始细胞<5%,骨髓RS≥15%(SF3B1突变时≥5%)。
  • MDS/MPN-RS-T诊断标准:具备MDS-RS-SLD特征,血小板≥450×10⁹/L,可见大而不典型巨核细胞。
  • SF3B1突变见于≥80%的MDS-RS-SLD和MDS/MPN-RS-T患者。
  • MDS/MPN-RS-T中阿司匹林治疗合理,尤其伴JAK2V617F时;降血小板药物的价值仍不确定。

临床怎么用

  • 贫血和铁过载按低危MDS和MPN的原则管理。
  • luspatercept将大幅提升贫血管理能力。
  • MDS/MPN-RS-T中阿司匹林治疗合理,尤其伴JAK2V617F时;降血小板药物的价值仍不确定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS-RS) and RARS with thrombocytosis (RARS-T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T). DIAGNOSIS: MDS-RS is a lower-risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and ≥ 15% BM RS (≥5% in the presence of SF3B1 mutations). MDS/MPN-RS-T, now a formal entity in the MDS/MPN overlap syndromes, has diagnostic features of MDS-RS-SLD, along with a platelet count ≥450 × 10(9)/L and large atypical megakaryocytes. MUTATIONS AND KARYOTYPE: Mutations in SF3B1 are seen in ≥80% of patients with MDS-RS-SLD and MDS/MPN-RS-T, and strongly correlate with the presence of BM RS; MDS/MPN-RS-T patients also demonstrate JAK2V617F, ASXL1, DNMT3A, SETBP1, and TET2 mutations. Cytogenetic abnormalities are uncommon in both. RISK STRATIFICATION: Most patients with MDS-RS-SLD are stratified into lower-risk groups by the revised-IPSS. Disease outcome in MDS/MPN-RS-T is better than that of MDS-RS-SLD, but worse than that of essential thrombocythemia. Both diseases have a low risk of leukemic transformation. TREATMENT: Anemia and iron overload are complications seen in both and are managed similar to lower-risk MDS and MPN. The advent of luspatercept, a first-in-class erythroid maturation agent will tremendously boost the ability to manage anemia. Aspirin therapy is reasonable in MDS/MPN-RS-T, especially in the presence of JAK2V617F, but the value of platelet-lowering drugs remains uncertain.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". Am J Hematol. 2019. PMID: 30618061. doi:10.1002/ajh.25397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。